The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
Background Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group w...
Saved in:
| Published in: | BMC cancer Vol. 15; no. 1; p. 652 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BioMed Central
05.10.2015
BioMed Central Ltd Springer Nature B.V |
| Subjects: | |
| ISSN: | 1471-2407, 1471-2407 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC).
Methods
Eligible patients had HER2-negative, stage II/III BC. Women receiving (neo)-adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) were randomized to fast 24 h before and after commencing chemotherapy, or to eat according to the guidelines for healthy nutrition. Toxicity in the two groups was compared. Chemotherapy-induced DNA damage in peripheral blood mononuclear cells (PBMCs) was quantified by the level of γ-H2AX analyzed by flow cytometry.
Results
Thirteen patients were included of whom seven were randomized to the STF arm. STF was well tolerated. Mean erythrocyte- and thrombocyte counts 7 days post-chemotherapy were significantly higher (
P = 0.007,
95 % CI 0.106-0.638 and
P = 0.00007,
95 % CI 38.7-104, respectively) in the STF group compared to the non-STF group. Non-hematological toxicity did not differ between the groups. Levels of γ-H2AX were significantly increased 30 min post-chemotherapy in CD45 + CD3- cells in non-STF, but not in STF patients.
Conclusions
STF during chemotherapy was well tolerated and reduced hematological toxicity of TAC in HER2-negative BC patients. Moreover, STF may reduce a transient increase in, and/or induce a faster recovery of DNA damage in PBMCs after chemotherapy. Larger studies, investigating a longer fasting period, are required to generate more insight into the possible benefits of STF during chemotherapy.
Trial registration
ClinicalTrials.gov:
NCT01304251
, March 2011 |
|---|---|
| AbstractList | BACKGROUNDPreclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC).METHODSEligible patients had HER2-negative, stage II/III BC. Women receiving (neo)-adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) were randomized to fast 24 h before and after commencing chemotherapy, or to eat according to the guidelines for healthy nutrition. Toxicity in the two groups was compared. Chemotherapy-induced DNA damage in peripheral blood mononuclear cells (PBMCs) was quantified by the level of γ-H2AX analyzed by flow cytometry.RESULTSThirteen patients were included of whom seven were randomized to the STF arm. STF was well tolerated. Mean erythrocyte- and thrombocyte counts 7 days post-chemotherapy were significantly higher (P = 0.007, 95 % CI 0.106-0.638 and P = 0.00007, 95 % CI 38.7-104, respectively) in the STF group compared to the non-STF group. Non-hematological toxicity did not differ between the groups. Levels of γ-H2AX were significantly increased 30 min post-chemotherapy in CD45 + CD3- cells in non-STF, but not in STF patients.CONCLUSIONSSTF during chemotherapy was well tolerated and reduced hematological toxicity of TAC in HER2-negative BC patients. Moreover, STF may reduce a transient increase in, and/or induce a faster recovery of DNA damage in PBMCs after chemotherapy. Larger studies, investigating a longer fasting period, are required to generate more insight into the possible benefits of STF during chemotherapy.TRIAL REGISTRATIONClinicalTrials.gov: NCT01304251 , March 2011. Background Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC). Methods Eligible patients had HER2-negative, stage II/III BC. Women receiving (neo)-adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) were randomized to fast 24 h before and after commencing chemotherapy, or to eat according to the guidelines for healthy nutrition. Toxicity in the two groups was compared. Chemotherapy-induced DNA damage in peripheral blood mononuclear cells (PBMCs) was quantified by the level of [gamma]-H2AX analyzed by flow cytometry. Results Thirteen patients were included of whom seven were randomized to the STF arm. STF was well tolerated. Mean erythrocyte- and thrombocyte counts 7 days post-chemotherapy were significantly higher (P = 0.007, 95 % CI 0.106-0.638 and P = 0.00007, 95 % CI 38.7-104, respectively) in the STF group compared to the non-STF group. Non-hematological toxicity did not differ between the groups. Levels of [gamma]-H2AX were significantly increased 30 min post-chemotherapy in CD45 + CD3- cells in non-STF, but not in STF patients. Conclusions STF during chemotherapy was well tolerated and reduced hematological toxicity of TAC in HER2-negative BC patients. Moreover, STF may reduce a transient increase in, and/or induce a faster recovery of DNA damage in PBMCs after chemotherapy. Larger studies, investigating a longer fasting period, are required to generate more insight into the possible benefits of STF during chemotherapy. Trial registration ClinicalTrials.gov: NCT01304251, March 2011 Keywords: Early stage breast cancer, Chemotherapy, Short-term fasting, Toxicity, DNA damage Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC). Eligible patients had HER2-negative, stage II/III BC. Women receiving (neo)-adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) were randomized to fast 24 h before and after commencing chemotherapy, or to eat according to the guidelines for healthy nutrition. Toxicity in the two groups was compared. Chemotherapy-induced DNA damage in peripheral blood mononuclear cells (PBMCs) was quantified by the level of γ-H2AX analyzed by flow cytometry. Thirteen patients were included of whom seven were randomized to the STF arm. STF was well tolerated. Mean erythrocyte- and thrombocyte counts 7 days post-chemotherapy were significantly higher (P = 0.007, 95 % CI 0.106-0.638 and P = 0.00007, 95 % CI 38.7-104, respectively) in the STF group compared to the non-STF group. Non-hematological toxicity did not differ between the groups. Levels of γ-H2AX were significantly increased 30 min post-chemotherapy in CD45 + CD3- cells in non-STF, but not in STF patients. STF during chemotherapy was well tolerated and reduced hematological toxicity of TAC in HER2-negative BC patients. Moreover, STF may reduce a transient increase in, and/or induce a faster recovery of DNA damage in PBMCs after chemotherapy. Larger studies, investigating a longer fasting period, are required to generate more insight into the possible benefits of STF during chemotherapy. ClinicalTrials.gov: NCT01304251 , March 2011. Background Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC). Methods Eligible patients had HER2-negative, stage II/III BC. Women receiving (neo)-adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) were randomized to fast 24 h before and after commencing chemotherapy, or to eat according to the guidelines for healthy nutrition. Toxicity in the two groups was compared. Chemotherapy-induced DNA damage in peripheral blood mononuclear cells (PBMCs) was quantified by the level of γ-H2AX analyzed by flow cytometry. Results Thirteen patients were included of whom seven were randomized to the STF arm. STF was well tolerated. Mean erythrocyte- and thrombocyte counts 7 days post-chemotherapy were significantly higher (P = 0.007, 95 % CI 0.106-0.638 and P = 0.00007, 95 % CI 38.7-104, respectively) in the STF group compared to the non-STF group. Non-hematological toxicity did not differ between the groups. Levels of γ-H2AX were significantly increased 30 min post-chemotherapy in CD45 + CD3- cells in non-STF, but not in STF patients. Conclusions STF during chemotherapy was well tolerated and reduced hematological toxicity of TAC in HER2-negative BC patients. Moreover, STF may reduce a transient increase in, and/or induce a faster recovery of DNA damage in PBMCs after chemotherapy. Larger studies, investigating a longer fasting period, are required to generate more insight into the possible benefits of STF during chemotherapy. Background Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC). Methods Eligible patients had HER2-negative, stage II/III BC. Women receiving (neo)-adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) were randomized to fast 24 h before and after commencing chemotherapy, or to eat according to the guidelines for healthy nutrition. Toxicity in the two groups was compared. Chemotherapy-induced DNA damage in peripheral blood mononuclear cells (PBMCs) was quantified by the level of γ-H2AX analyzed by flow cytometry. Results Thirteen patients were included of whom seven were randomized to the STF arm. STF was well tolerated. Mean erythrocyte- and thrombocyte counts 7 days post-chemotherapy were significantly higher ( P = 0.007, 95 % CI 0.106-0.638 and P = 0.00007, 95 % CI 38.7-104, respectively) in the STF group compared to the non-STF group. Non-hematological toxicity did not differ between the groups. Levels of γ-H2AX were significantly increased 30 min post-chemotherapy in CD45 + CD3- cells in non-STF, but not in STF patients. Conclusions STF during chemotherapy was well tolerated and reduced hematological toxicity of TAC in HER2-negative BC patients. Moreover, STF may reduce a transient increase in, and/or induce a faster recovery of DNA damage in PBMCs after chemotherapy. Larger studies, investigating a longer fasting period, are required to generate more insight into the possible benefits of STF during chemotherapy. Trial registration ClinicalTrials.gov: NCT01304251 , March 2011 Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot study examines the feasibility of STF and its effects on tolerance of chemotherapy in a homogeneous patient group with early breast cancer (BC). Eligible patients had HER2-negative, stage II/III BC. Women receiving (neo)-adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) were randomized to fast 24 h before and after commencing chemotherapy, or to eat according to the guidelines for healthy nutrition. Toxicity in the two groups was compared. Chemotherapy-induced DNA damage in peripheral blood mononuclear cells (PBMCs) was quantified by the level of [gamma]-H2AX analyzed by flow cytometry. Thirteen patients were included of whom seven were randomized to the STF arm. STF was well tolerated. Mean erythrocyte- and thrombocyte counts 7 days post-chemotherapy were significantly higher (P = 0.007, 95 % CI 0.106-0.638 and P = 0.00007, 95 % CI 38.7-104, respectively) in the STF group compared to the non-STF group. Non-hematological toxicity did not differ between the groups. Levels of [gamma]-H2AX were significantly increased 30 min post-chemotherapy in CD45 + CD3- cells in non-STF, but not in STF patients. STF during chemotherapy was well tolerated and reduced hematological toxicity of TAC in HER2-negative BC patients. Moreover, STF may reduce a transient increase in, and/or induce a faster recovery of DNA damage in PBMCs after chemotherapy. Larger studies, investigating a longer fasting period, are required to generate more insight into the possible benefits of STF during chemotherapy. |
| ArticleNumber | 652 |
| Audience | Academic |
| Author | van der Hoeven, Jacobus JM de Groot, Stefanie Gravesteijn, Gido Putter, Hein Jochems, Anouk Boei, Jan JWA Nortier, Johan WR Pijl, Hanno Houtsma, Daniel Kroep, Judith R Vreeswijk, Maaike PG Welters, Marij JP |
| Author_xml | – sequence: 1 givenname: Stefanie surname: de Groot fullname: de Groot, Stefanie organization: Department of Medical Oncology, Leiden University Medical Center – sequence: 2 givenname: Maaike PG surname: Vreeswijk fullname: Vreeswijk, Maaike PG organization: Department of Human Genetics, Leiden University Medical Center – sequence: 3 givenname: Marij JP surname: Welters fullname: Welters, Marij JP organization: Department of Medical Oncology, Leiden University Medical Center – sequence: 4 givenname: Gido surname: Gravesteijn fullname: Gravesteijn, Gido organization: Department of Human Genetics, Leiden University Medical Center – sequence: 5 givenname: Jan JWA surname: Boei fullname: Boei, Jan JWA organization: Department of Human Genetics, Leiden University Medical Center – sequence: 6 givenname: Anouk surname: Jochems fullname: Jochems, Anouk organization: Department of Medical Oncology, Leiden University Medical Center – sequence: 7 givenname: Daniel surname: Houtsma fullname: Houtsma, Daniel organization: Department of Internal Medicine, Haga Hospital – sequence: 8 givenname: Hein surname: Putter fullname: Putter, Hein organization: Department of Medical Statistics, Leiden University Medical Center – sequence: 9 givenname: Jacobus JM surname: van der Hoeven fullname: van der Hoeven, Jacobus JM organization: Department of Medical Oncology, Leiden University Medical Center – sequence: 10 givenname: Johan WR surname: Nortier fullname: Nortier, Johan WR organization: Department of Medical Oncology, Leiden University Medical Center – sequence: 11 givenname: Hanno surname: Pijl fullname: Pijl, Hanno organization: Department of Endocrinology, Leiden University Medical Center – sequence: 12 givenname: Judith R surname: Kroep fullname: Kroep, Judith R email: J.R.Kroep@lumc.nl organization: Department of Medical Oncology, Leiden University Medical Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26438237$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl9r1TAYxotM3B_9AN5IQJDtojNpkybdhTDGdIOBMOd1SNO3bUabHJP04PFL-JXN4Wx6zlDJRcKb3_MkefMcZnvWWciy1wSfEiKq94EUQrAcE5aTqipz9iw7IJSTvKCY722t97PDEO4xJlxg8SLbLypaiqLkB9nPuwEQdB3oGJDrUBicj3kEP6FOhWhsj5xF0Y3gldWQVujYgjtBqr2fl8pGpAeYXBzS_mKFjEVXl7dFbqFX0SwBNR6SDdJrsUeLVAQbwxlSKPm1bjI_oEULM7qIQpzb1cvseafGAK8e5qPs68fLu4ur_Obzp-uL85tcV5WIOcFQNlDTRitaKNpBI3CjS40rTBnmhVK41iUvNcdCCOhqgYG1ndKEVwXTdXmUfdj4LuZmglanW3k1yoU3k_Ir6ZSRuzvWDLJ3S0lZzTAjyeD4wcC7bzOEKCcTNIyjSu2ZgySc1DVnFRYJffsEvXezt-l5ieK1KGglyB-qVyNIYzuXztVrU3nOKKE4fRpN1OlfqDRamIxO8ehMqu8ITnYEiYnwPfZqDkFef7ndZd9tsQOoMQ7BjXM0zoZd8M1293637TFXCeAbQHsXgodOahPV2idd14ySYLlOsNwkWKYEy3WCJUtK8kT5aP4_TbHRhMTaHvxWg_8p-gVyDAFZ |
| CitedBy_id | crossref_primary_10_3390_v11070614 crossref_primary_10_1016_j_clnu_2016_07_015 crossref_primary_10_1080_2162402X_2019_1591878 crossref_primary_10_3390_cancers14205149 crossref_primary_10_3390_jcm13102771 crossref_primary_10_1186_s12885_020_07041_7 crossref_primary_10_1186_s12885_024_12752_2 crossref_primary_10_1007_s10552_021_01401_9 crossref_primary_10_3390_nu15122749 crossref_primary_10_1007_s00520_020_05879_y crossref_primary_10_1016_j_jand_2017_08_112 crossref_primary_10_1016_j_ejmech_2016_08_067 crossref_primary_10_3390_nu14122536 crossref_primary_10_3390_nu15204408 crossref_primary_10_7759_cureus_67434 crossref_primary_10_1016_j_critrevonc_2020_103061 crossref_primary_10_1093_nutrit_nuae109 crossref_primary_10_3389_fcell_2020_590192 crossref_primary_10_1186_s12885_018_4778_7 crossref_primary_10_1159_000540068 crossref_primary_10_12968_bjon_2018_27_4_S4 crossref_primary_10_1007_s15013_016_0995_9 crossref_primary_10_1093_nutrit_nuad130 crossref_primary_10_3322_caac_21694 crossref_primary_10_1159_000496096 crossref_primary_10_1186_s12885_019_5931_7 crossref_primary_10_1186_s12916_017_0873_x crossref_primary_10_1080_13813455_2025_2550470 crossref_primary_10_7748_ns_2023_e11963 crossref_primary_10_3390_cancers13164013 crossref_primary_10_1007_s40137_018_0208_7 crossref_primary_10_1016_j_cmet_2024_06_014 crossref_primary_10_1080_01635581_2024_2437833 crossref_primary_10_1007_s44178_023_00058_5 crossref_primary_10_1016_j_clnu_2020_10_037 crossref_primary_10_1002_ange_202208570 crossref_primary_10_1186_s40814_019_0505_7 crossref_primary_10_1159_000484045 crossref_primary_10_1002_cpt_2094 crossref_primary_10_1016_j_tem_2018_01_008 crossref_primary_10_1038_s41416_021_01650_0 crossref_primary_10_1177_10732748211009256 crossref_primary_10_1172_JCI137552 crossref_primary_10_1007_s12032_022_01923_5 crossref_primary_10_1186_s12885_018_4353_2 crossref_primary_10_1007_s10555_022_10043_5 crossref_primary_10_1146_annurev_nutr_013120_041149 crossref_primary_10_1093_advances_nmab132 crossref_primary_10_1038_s41467_022_33352_3 crossref_primary_10_1016_j_critrevonc_2018_01_002 crossref_primary_10_15252_embr_202050635 crossref_primary_10_1111_vco_12638 crossref_primary_10_3390_hemato5040031 crossref_primary_10_1186_s13063_020_04700_9 crossref_primary_10_1080_15548627_2021_1897961 crossref_primary_10_1080_01635581_2025_2527426 crossref_primary_10_1186_s12885_025_13806_9 crossref_primary_10_1038_s41568_020_0295_5 crossref_primary_10_1186_s12935_021_02416_7 crossref_primary_10_1016_j_bbcan_2025_189322 crossref_primary_10_3917_spub_224_0481 crossref_primary_10_1038_s41568_018_0098_0 crossref_primary_10_1186_s13058_019_1180_6 crossref_primary_10_1089_acm_2018_0150 crossref_primary_10_1002_advs_202204487 crossref_primary_10_1097_COC_0000000000000749 crossref_primary_10_1097_TIN_0000000000000215 crossref_primary_10_1016_j_cytogfr_2018_10_005 crossref_primary_10_1016_j_smim_2023_101840 crossref_primary_10_3389_fonc_2023_1222573 crossref_primary_10_3390_jpm14030305 crossref_primary_10_3390_nu14194216 crossref_primary_10_1016_j_semcancer_2020_09_010 crossref_primary_10_1007_s11136_022_03300_1 crossref_primary_10_3389_fnut_2024_1483707 crossref_primary_10_1093_jnci_djaa060 crossref_primary_10_3390_nu13103421 crossref_primary_10_1159_000542155 crossref_primary_10_3389_fonc_2020_00578 crossref_primary_10_1007_s11060_025_05137_3 crossref_primary_10_3390_ph13100292 crossref_primary_10_1016_j_ctrv_2024_102725 crossref_primary_10_3390_biom9100530 crossref_primary_10_1186_s12929_020_00651_0 crossref_primary_10_1038_s41568_018_0061_0 crossref_primary_10_1016_j_heliyon_2023_e22814 crossref_primary_10_1186_s12885_018_4245_5 crossref_primary_10_1007_s10555_022_10061_3 crossref_primary_10_1080_09553002_2017_1380330 crossref_primary_10_1016_j_nupar_2020_05_002 crossref_primary_10_1111_bjhp_12358 crossref_primary_10_1080_17425255_2020_1706728 crossref_primary_10_3390_cancers14061390 crossref_primary_10_1177_17588359231161418 crossref_primary_10_3390_nu15122666 crossref_primary_10_1016_j_bbcan_2023_189062 crossref_primary_10_3390_cancers13184587 crossref_primary_10_3390_nu11102501 crossref_primary_10_1097_JN9_0000000000000015 crossref_primary_10_1016_j_clnu_2021_02_005 crossref_primary_10_1111_cas_15492 crossref_primary_10_1158_2159_8290_CD_23_1165 crossref_primary_10_1016_j_arr_2017_02_001 crossref_primary_10_3389_fendo_2021_632284 crossref_primary_10_3389_fnut_2021_642628 crossref_primary_10_1007_s00520_025_09907_7 crossref_primary_10_3390_microorganisms8081140 crossref_primary_10_3389_fonc_2016_00027 crossref_primary_10_1007_s10522_025_10301_3 crossref_primary_10_3390_nu11071514 crossref_primary_10_3389_fcell_2022_803280 crossref_primary_10_1038_s41568_019_0198_5 crossref_primary_10_3390_ijms21239175 crossref_primary_10_1038_nrclinonc_2016_183 crossref_primary_10_3390_plants13010035 crossref_primary_10_2174_0109298673275492231121062033 crossref_primary_10_3390_nu12092823 crossref_primary_10_3390_nu13093268 crossref_primary_10_1007_s00120_018_0632_4 crossref_primary_10_1146_annurev_cancerbio_060820_090737 crossref_primary_10_5812_ijcm_107678 crossref_primary_10_1016_j_banm_2021_01_022 crossref_primary_10_7759_cureus_81395 crossref_primary_10_1038_s41467_020_16138_3 crossref_primary_10_1002_ijc_31646 crossref_primary_10_3390_nu15214677 crossref_primary_10_1158_2159_8290_CD_21_0030 crossref_primary_10_1007_s10549_025_07756_w crossref_primary_10_1097_CCO_0000000000000986 crossref_primary_10_3390_cancers16112079 crossref_primary_10_1038_s41568_018_0100_x crossref_primary_10_6061_clinics_2018_e814s crossref_primary_10_1016_j_critrevonc_2024_104571 crossref_primary_10_1002_anie_202208570 crossref_primary_10_1016_j_ygyno_2020_09_008 crossref_primary_10_1186_s13045_022_01238_y crossref_primary_10_1007_s13402_024_00966_2 crossref_primary_10_1007_s11357_020_00317_7 crossref_primary_10_1007_s13105_024_01020_3 crossref_primary_10_1159_000510839 crossref_primary_10_1038_s41387_024_00275_5 crossref_primary_10_1007_s11764_025_01777_6 crossref_primary_10_1016_j_gore_2025_101718 crossref_primary_10_1007_s10549_020_05991_x crossref_primary_10_3390_nu12010114 crossref_primary_10_1016_j_ijrobp_2019_06_2533 crossref_primary_10_1126_scitranslmed_abn9061 crossref_primary_10_1002_advs_202200482 crossref_primary_10_1007_s00129_019_4459_x crossref_primary_10_1007_s40262_017_0515_7 crossref_primary_10_1177_2515690X20949444 crossref_primary_10_1016_j_dnarep_2020_102949 crossref_primary_10_3389_fimmu_2025_1488324 crossref_primary_10_1016_j_cmet_2021_08_018 crossref_primary_10_3390_nu14102001 crossref_primary_10_1007_s00761_020_00852_0 crossref_primary_10_1038_s41467_021_22922_6 crossref_primary_10_1038_s41467_021_26431_4 crossref_primary_10_3390_cells13100806 crossref_primary_10_1016_j_clnesp_2024_06_046 crossref_primary_10_1007_s00120_018_0638_y crossref_primary_10_3390_nu15030532 crossref_primary_10_3390_nu14183809 crossref_primary_10_3389_fonc_2016_00242 crossref_primary_10_3390_cancers15030777 crossref_primary_10_1158_2159_8290_CD_16_0615 |
| Cites_doi | 10.1016/S0140-6736(04)16044-3 10.1016/j.cell.2012.03.017 10.1016/j.ijrobp.2003.09.028 10.1371/journal.pone.0018085 10.1093/annonc/mdu102 10.1159/000336500 10.1093/jnci/djp025 10.1016/j.cmet.2013.12.008 10.1152/ajpendo.00613.2006 10.1038/nrm3025 10.1016/j.radonc.2006.07.026 10.1152/ajpendo.00008.2013 10.1074/jbc.M310030200 10.1186/1748-717X-8-155 10.1038/sj.ijo.0801671 10.1016/0026-0495(90)90043-C 10.1016/j.coi.2008.05.007 10.1016/j.ijrobp.2010.08.004 10.1371/journal.pone.0044603 10.1158/1078-0432.CCR-07-5147 10.1126/science.1173635 10.1007/s00404-010-1609-8 10.1056/NEJMra020526 10.18632/aging.100114 10.1111/j.1474-9726.2008.00417.x 10.1073/pnas.0708100105 10.1016/j.ijrobp.2009.08.052 10.1093/annonc/mdm438 10.3322/canjclin.56.6.323 10.1038/onc.2011.91 10.1093/gerona/57.6.B211 10.1158/1078-0432.CCR-14-0968 10.1056/NEJMcibr1202395 10.1093/mutage/get024 10.1177/019262339502300403 10.1093/carcin/bgr107 10.1038/nrm3311 10.1016/j.asr.2008.10.011 10.1126/science.7063854 10.1002/ijc.25953 10.1016/j.cmet.2015.05.012 10.1126/science.1172539 10.1038/nrg2188 10.1126/scitranslmed.3003293 |
| ContentType | Journal Article |
| Copyright | de Groot et al. 2015 COPYRIGHT 2015 BioMed Central Ltd. Copyright BioMed Central 2015 |
| Copyright_xml | – notice: de Groot et al. 2015 – notice: COPYRIGHT 2015 BioMed Central Ltd. – notice: Copyright BioMed Central 2015 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7U8 7X8 C1K JXQ 5PM |
| DOI | 10.1186/s12885-015-1663-5 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management Toxline PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management |
| DatabaseTitleList | TOXLINE MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 652 |
| ExternalDocumentID | PMC4595051 4017029891 A541402644 26438237 10_1186_s12885_015_1663_5 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 0R~ 23N 2WC 4.4 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7U8 7X8 C1K JXQ 5PM |
| ID | FETCH-LOGICAL-c668t-10e3be94bca42a4feb80bc3c06045072aa09c373c70888ef980e5dfac17625c93 |
| IEDL.DBID | PIMPY |
| ISICitedReferencesCount | 189 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000362257500004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2407 |
| IngestDate | Tue Nov 04 01:57:23 EST 2025 Thu Oct 02 11:14:35 EDT 2025 Tue Oct 07 05:11:37 EDT 2025 Tue Nov 11 10:56:55 EST 2025 Tue Nov 04 18:24:00 EST 2025 Thu Nov 13 16:40:30 EST 2025 Thu May 22 21:24:04 EDT 2025 Mon Jul 21 05:51:09 EDT 2025 Tue Nov 18 20:49:34 EST 2025 Sat Nov 29 04:29:33 EST 2025 Sat Sep 06 07:24:32 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Chemotherapy Toxicity Early stage breast cancer DNA damage Short-term fasting |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c668t-10e3be94bca42a4feb80bc3c06045072aa09c373c70888ef980e5dfac17625c93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.proquest.com/publiccontent/docview/1779824681?pq-origsite=%requestingapplication% |
| PMID | 26438237 |
| PQID | 1779824681 |
| PQPubID | 44074 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4595051 proquest_miscellaneous_1719975608 proquest_journals_1779824681 gale_infotracmisc_A541402644 gale_infotracacademiconefile_A541402644 gale_incontextgauss_ISR_A541402644 gale_healthsolutions_A541402644 pubmed_primary_26438237 crossref_citationtrail_10_1186_s12885_015_1663_5 crossref_primary_10_1186_s12885_015_1663_5 springer_journals_10_1186_s12885_015_1663_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-10-05 |
| PublicationDateYYYYMMDD | 2015-10-05 |
| PublicationDate_xml | – month: 10 year: 2015 text: 2015-10-05 day: 05 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC cancer |
| PublicationTitleAbbrev | BMC Cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2015 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V |
| References | 1663_CR31 M Laplante (1663_CR46) 2012; 149 FM Safdie (1663_CR20) 2009; 1 V Grill (1663_CR40) 1990; 39 AG Renehan (1663_CR7) 2004; 363 L Fontana (1663_CR15) 2010; 328 LJ Kuo (1663_CR21) 2008; 22 P Li (1663_CR27) 2013; 8 C Lee (1663_CR10) 2012; 4 CE Rube (1663_CR29) 2010; 78 RL Walford (1663_CR8) 2002; 57 CE Redon (1663_CR25) 2009; 43 EC Bourton (1663_CR30) 2011; 129 A Tesniere (1663_CR39) 2008; 20 F Safdie (1663_CR12) 2012; 7 MA Wijngaarden (1663_CR18) 2013; 304 D Klokov (1663_CR24) 2006; 80 1663_CR43 M Snel (1663_CR49) 2012; 96 R Zoncu (1663_CR47) 2011; 12 R Scarpato (1663_CR48) 2013; 28 A Laviano (1663_CR13) 2012; 366 L Fontana (1663_CR6) 2008; 7 WG Sheldon (1663_CR1) 1995; 23 L Raffaghello (1663_CR11) 2008; 105 RJ Colman (1663_CR5) 2009; 325 T Hickish (1663_CR41) 2009; 101 CE Rube (1663_CR22) 2008; 14 BC Bergman (1663_CR19) 2007; 293 A Charehbili (1663_CR34) 2014; 25 N Hatam (1663_CR32) 2011; 284 NA Bishop (1663_CR16) 2007; 8 TJ Mulrooney (1663_CR2) 2011; 6 VD Longo (1663_CR14) 2014; 19 DG Hardie (1663_CR45) 2012; 13 A Thomas (1663_CR38) 2014; 20 J Fleckenstein (1663_CR28) 2011; 81 G Minckwitz von (1663_CR33) 2008; 19 N Taneja (1663_CR23) 2004; 279 JP Thissen (1663_CR37) 1994; 15 K Matsumoto (1663_CR42) 1996; 81 C Doyle (1663_CR9) 2006; 56 PL Olive (1663_CR26) 2004; 58 HJ Kim (1663_CR36) 2005; 28 M Maccario (1663_CR17) 2001; 25 MS Lorenzo De (1663_CR3) 2011; 32 R Weindruch (1663_CR4) 1982; 215 C Lee (1663_CR44) 2011; 30 WE Evans (1663_CR35) 2003; 348 S Brandhorst (1663_CR50) 2015; 22 |
| References_xml | – volume: 363 start-page: 1346 year: 2004 ident: 1663_CR7 publication-title: Lancet doi: 10.1016/S0140-6736(04)16044-3 – volume: 149 start-page: 274 year: 2012 ident: 1663_CR46 publication-title: Cell doi: 10.1016/j.cell.2012.03.017 – volume: 58 start-page: 331 year: 2004 ident: 1663_CR26 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2003.09.028 – volume: 6 start-page: e18085 year: 2011 ident: 1663_CR2 publication-title: PLoS One doi: 10.1371/journal.pone.0018085 – volume: 22 start-page: 305 year: 2008 ident: 1663_CR21 publication-title: In Vivo – volume: 25 start-page: 998 issue: 5 year: 2014 ident: 1663_CR34 publication-title: Ann Oncol doi: 10.1093/annonc/mdu102 – volume: 96 start-page: 285 year: 2012 ident: 1663_CR49 publication-title: Neuroendocrinology doi: 10.1159/000336500 – volume: 101 start-page: 537 year: 2009 ident: 1663_CR41 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djp025 – volume: 19 start-page: 181 year: 2014 ident: 1663_CR14 publication-title: Cell Metab doi: 10.1016/j.cmet.2013.12.008 – volume: 81 start-page: 2621 year: 1996 ident: 1663_CR42 publication-title: J Clin Endocrinol Metab – volume: 293 start-page: E1103 year: 2007 ident: 1663_CR19 publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00613.2006 – volume: 12 start-page: 21 year: 2011 ident: 1663_CR47 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm3025 – volume: 80 start-page: 223 year: 2006 ident: 1663_CR24 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2006.07.026 – volume: 304 start-page: E1012 issue: 9 year: 2013 ident: 1663_CR18 publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00008.2013 – volume: 279 start-page: 2273 year: 2004 ident: 1663_CR23 publication-title: J Biol Chem doi: 10.1074/jbc.M310030200 – ident: 1663_CR31 – volume: 15 start-page: 80 year: 1994 ident: 1663_CR37 publication-title: Endocr Rev – volume: 8 start-page: 155 year: 2013 ident: 1663_CR27 publication-title: Radiat Oncol doi: 10.1186/1748-717X-8-155 – volume: 25 start-page: 1233 year: 2001 ident: 1663_CR17 publication-title: Int J Obes Relat Metab Disord doi: 10.1038/sj.ijo.0801671 – volume: 39 start-page: 251 year: 1990 ident: 1663_CR40 publication-title: Metabolism doi: 10.1016/0026-0495(90)90043-C – volume: 20 start-page: 504 year: 2008 ident: 1663_CR39 publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2008.05.007 – volume: 81 start-page: 1465 year: 2011 ident: 1663_CR28 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2010.08.004 – volume: 7 start-page: e44603 year: 2012 ident: 1663_CR12 publication-title: PLoS One doi: 10.1371/journal.pone.0044603 – volume: 14 start-page: 6546 year: 2008 ident: 1663_CR22 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-5147 – volume: 325 start-page: 201 year: 2009 ident: 1663_CR5 publication-title: Science doi: 10.1126/science.1173635 – volume: 284 start-page: 215 year: 2011 ident: 1663_CR32 publication-title: Arch Gynecol Obstet doi: 10.1007/s00404-010-1609-8 – volume: 348 start-page: 538 year: 2003 ident: 1663_CR35 publication-title: N Engl J Med doi: 10.1056/NEJMra020526 – volume: 1 start-page: 988 year: 2009 ident: 1663_CR20 publication-title: Aging (Albany NY) doi: 10.18632/aging.100114 – volume: 7 start-page: 681 year: 2008 ident: 1663_CR6 publication-title: Aging Cell doi: 10.1111/j.1474-9726.2008.00417.x – volume: 105 start-page: 8215 year: 2008 ident: 1663_CR11 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0708100105 – volume: 78 start-page: 359 year: 2010 ident: 1663_CR29 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2009.08.052 – volume: 19 start-page: 292 year: 2008 ident: 1663_CR33 publication-title: Ann Oncol doi: 10.1093/annonc/mdm438 – volume: 56 start-page: 323 year: 2006 ident: 1663_CR9 publication-title: CA Cancer J Clin doi: 10.3322/canjclin.56.6.323 – volume: 30 start-page: 3305 year: 2011 ident: 1663_CR44 publication-title: Oncogene doi: 10.1038/onc.2011.91 – volume: 57 start-page: B211 year: 2002 ident: 1663_CR8 publication-title: J Gerontol A Biol Sci Med Sci doi: 10.1093/gerona/57.6.B211 – volume: 20 start-page: 5392 issue: 21 year: 2014 ident: 1663_CR38 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-0968 – volume: 366 start-page: 2319 year: 2012 ident: 1663_CR13 publication-title: N Engl J Med doi: 10.1056/NEJMcibr1202395 – volume: 28 start-page: 465 year: 2013 ident: 1663_CR48 publication-title: Mutagenesis doi: 10.1093/mutage/get024 – volume: 23 start-page: 458 year: 1995 ident: 1663_CR1 publication-title: Toxicol Pathol doi: 10.1177/019262339502300403 – volume: 32 start-page: 1381 year: 2011 ident: 1663_CR3 publication-title: Carcinogenesis doi: 10.1093/carcin/bgr107 – volume: 13 start-page: 251 year: 2012 ident: 1663_CR45 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm3311 – volume: 43 start-page: 1171 year: 2009 ident: 1663_CR25 publication-title: Adv Space Res doi: 10.1016/j.asr.2008.10.011 – volume: 28 start-page: 270 year: 2005 ident: 1663_CR36 publication-title: Cancer Nurs – volume: 215 start-page: 1415 year: 1982 ident: 1663_CR4 publication-title: Science doi: 10.1126/science.7063854 – volume: 129 start-page: 2928 year: 2011 ident: 1663_CR30 publication-title: Int J Cancer doi: 10.1002/ijc.25953 – volume: 22 start-page: 86 year: 2015 ident: 1663_CR50 publication-title: Cell Metab doi: 10.1016/j.cmet.2015.05.012 – ident: 1663_CR43 – volume: 328 start-page: 321 year: 2010 ident: 1663_CR15 publication-title: Science doi: 10.1126/science.1172539 – volume: 8 start-page: 835 year: 2007 ident: 1663_CR16 publication-title: Nat Rev Genet doi: 10.1038/nrg2188 – volume: 4 start-page: 124ra27 year: 2012 ident: 1663_CR10 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3003293 |
| SSID | ssj0017808 |
| Score | 2.552189 |
| Snippet | Background
Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more... Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more vulnerable to... Background Preclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more... BACKGROUNDPreclinical evidence shows that short-term fasting (STF) protects healthy cells against side effects of chemotherapy and makes cancer cells more... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 652 |
| SubjectTerms | Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology Calories Cancer Research Care and treatment Chemotherapy Cloning Comparative analysis Complications and side effects DNA Damage Fasting Female Growth factors Health aspects Health Promotion and Disease Prevention Histones - metabolism Human subjects Humans Insulin Laboratories Leukocytes, Mononuclear - metabolism Medicine/Public Health Metabolism Middle Aged Neoadjuvant Therapy Neoplasm Grading Neoplasm Staging Oncology Patients Pilot Projects Receptor, ErbB-2 - deficiency Research Article Surgical Oncology Time Factors Toxicity Treatment Outcome |
| SummonAdditionalLinks | – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagINQL70eggEFIUFBEXk4cbhVqVQ5UaAuoN8t27DbVNqk2WST4E_xlZhxv1KwACW6RPE6cycx4ovn8DSEvqipTYBYsZMrCD0pRmBCyjDI0ldVxolhmmXLNJoqDA350VH7y57i7Fdp9VZJ0kdq5Nc_fdhBJOQLNWBjDNhmyy-QK7HYcvXF2-HUsHRQ84r58-dtpkw1oPQxf2IfWMZJrhVK3_-zd-K-V3yTXfbpJdwb7uEUumeY2ufbRF9TvkJ9gJtRjOmhraXcC6XiI4Zpa2SEkmrYN7du5wQYcBq7oq8a021RWp0tIwnsKH_3Mn-L6TuuG7u_OkrAxx45QnCrEvIMQTl5QT-LavaOSwv2q9qz-YSp6Xs_bnjqi27vky97u5_f7oe_REOo85z1EcZMqU2ZKyyyRmTWKR0qnGjl5INVMpIxKnRapLiCccWNLHhlWWaljiMJMl-k9stG0jXlAaKyzOMZOFWA2kGZUpZGsUplVZazyKucBiVYfTmhPYI59NObC_cjwXAyKFqBogYoWLCCvxynnA3vH34SfojWI4QDq6PliBzulR5g4BuS5k0DejAaBOcdy2XXiw-FsIvTSC9kWlqelP-cAL4lUWxPJrYkkOLaeDq_MUvjA0okYHIknWc7jgDwbh3EmguXAAJYog-ghSGVBZfcHKx7fHm6Mld8iIMXEvkcBpBufjjT1iaMdz1gJ6TI8983Kyi8s609KffhP0o_IZuLcBAEaW2SjXyzNY3JVf-vrbvHE-fkv77ZPjw priority: 102 providerName: Springer Nature |
| Title | The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study |
| URI | https://link.springer.com/article/10.1186/s12885-015-1663-5 https://www.ncbi.nlm.nih.gov/pubmed/26438237 https://www.proquest.com/docview/1779824681 https://www.proquest.com/docview/1719975608 https://pubmed.ncbi.nlm.nih.gov/PMC4595051 |
| Volume | 15 |
| WOSCitedRecordID | wos000362257500004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF7RBKFeeEMDJSwIiZes2I4fay6ooFTtoVGUAgqn1b7cBqV2iB0k-BP8ZWbsjakj0ROXKNHOrr3O52_HntlvCHmhdSABFqETyhQeUOLYOOBlJI7RqfJ8GQZpKKtiE_F4zGazZGK3Rxc2rXLDiRVR12rPmLcNJDzQucI35gMPxmN-EDHv_fK7gzWkMNZqC2rskC4Kb7EO6U6OTyZfm6hCzFxmI5seiwYFcDPD1LXQ8WDhdcLW2rTN0JeWqO30ya0YarU0Hd76v5O6TW5aF5Ue1Ji6Q66Z7C65cWKD8PfIb4AWtXkgNE9pcQ4uvIMUT1NRYBo1zTNa5guDRTsMfKOvMpO_pkJ_W4PjXlIAyoXd-fWTzjN6NJr6TmbOKhFyKjFPHoyw84pa4dfiHRUUxtP5xfyX0XQ5X-QlrcRx75PPh6NPH48cW9fBUVHESmB-M5QmCaQSgS-C1EjmSjVUqOMD7qkvhJuoYTxUMVAgM2nCXBPqVCgPmDtUyfAB6WR5ZvYI9VTgeVjdAqAGrolOjAi1DFKZeDLSEesRd_OPcmVFz7H2xoJXDz8s4jUIOICAIwh42CNvmi7LWvHjKuOnCBNeb1pt2IIfYHV1F53NHnleWaDWRobJPGdiXRT8-HTaMnppjdIcTk8JuzcCJonyXC3L_ZYlkIFqN2-Axi0ZFfwvrnrkWdOMPTHBDgCwRhvMOAL3Fy7ZwxrezexhYIwWxz0St4DfGKBEebslm59XUuVBmICLDcd9u7lFLp3Wvy7qo6sn8Zjs-tU9i1kc-6RTrtbmCbmufpTzYtUnO_Esrj5Zn3Q_jMaTab960dK3bAC_pqdf_gCcMGyI |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3bbtNAEF1VBQEv3C-BQhcE4iartuO110gIVdAqUdsIlSLlbfFe3AaldogdUPkJ_oRvZMZemzoSfesDb5E8u_FuZs7MZM_OEPJU60CCWjCHyRQSlCgyDkQZsWN0qjxfsiBlsmo2EY1GfDyOP66Q381dGKRVNphYAbXOFf5HvuHBDNwPQu69m31zsGsUnq42LTRqtdgxJz8gZSveDj_A7_vM97e3Dt4PHNtVwFFhyEvAHdOXJg6kSgI_CVIjuStVX2EVGQiO_CRxY9WP-ioCA-QmjblrmE4T5QFuMIXFlwDyLwCOR0ghi8ZtgudF3OX25NTj4UYB2M-RGsccDxy7wzq-b9kDnHKBy_TMpTPayvVtX_vfNu06uWqDbLpZW8UNsmKym-TSnqUR3CK_wDioZbLQPKXFESQhDjopmiYFEsFpntEynxpsO2LgE32RmfwlTfTXBaQeJQVVP7Z3107oJKODrX3fycxhVUadSmT6gxAOnlNburZ4QxMK8-n8ePLTaDqbTPOSVuV9b5PP57Idd8hqlmfmHqGeCjwP-3OAsUBwpWOTMC2DVMaeDHXIe8RtdEYoW7Ydu4dMRZW-8VDUaiZAzQSqmWA98qodMqtrlpwlvI6KKOprty3eiU3sD-9iuNwjTyoJrBaSIR3pMFkUhRh-2u8IPbdCaQ6vpxJ7uwMWiQXGOpJrHUmAM9V93KiysHBaiL963COP28c4EimCoAALlEHOFATwsGV3awNqVw8T43l31CNRx7RaASyy3n2STY6qYusBiyFJgO993Rjhqdf616beP3sR6-Ty4GBvV-wORzsPyBW_QgjkpKyR1XK-MA_JRfW9nBTzRxW-UPLlvG3zD2L_tys |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ta9RAEF60SukX362n1a4i-EZokssmG78V7dGiHqXV0m_LvrYn1-S45AT9E_5lZ5K90BwqiN8OdjaXnTwzO8vMPkPIc2MSBbBgAVMODihZZgOIMvLAGqejWLHEMdU0m8jGY356mh_6PqfVstp9mZJs7zQgS1NR78yMa02cpzsVeFWORWcsiGDLDNhVci3BnkF4XD8-6dIIGQ-5T2X-dlpvM1p1yZf2pNV6yZWkabMXjW7-9ypukRs-DKW7LW5ukyu2uEPWP_lE-13yE-BDfa0HLR2tziFMD9CNUycrLJWmZUHrcmqxMYeFX_RlYctXVJqvCwjOawpguPC3u77TSUH3947ioLBnDdE4VVgLD0I4eU49uWv1lkoKzzPlxeSHNXQ2mZY1bQhw75Evo73P7_YD37sh0GnKa_Dudqhsnigtk1gmzioeKj3UyNUDIWgsZZjrYTbUGbg5bl3OQ8uMkzoC78x0PrxP1oqysA8IjXQSRdjBAuAE4YfJrWRGJU7lkUpNygckXH5EoT2xOfbXmIrmgMNT0SpagKIFKlqwAXndTZm1rB5_E95GZIj2YmrnEcQudlAPMaAckGeNBPJpFFiwcyYXVSUOjo96Qi-8kCvh9bT09x9gkUjB1ZPc6kmCwev-8BKiwjucSkRgYDxOUh4NyNNuGGdiER0AYIEyWFUEIS6obLNFdLd6eDBmhLMByXpY7wSQhrw_UkzOGzryhOUQRsP_vlki_tJr_UmpD_9JepusH74fiY8H4w-PyEbcWAzWcGyRtXq-sI_Jdf2tnlTzJ435_wKw1FtX |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effects+of+short-term+fasting+on+tolerance+to+%28neo%29+adjuvant+chemotherapy+in+HER2-negative+breast+cancer+patients%3A+a+randomized+pilot+study&rft.jtitle=BMC+cancer&rft.au=de+Groot%2C+Stefanie&rft.au=Vreeswijk%2C+Maaike+P+G&rft.au=Welters%2C+Marij+J+P&rft.au=Gravesteijn%2C+Gido&rft.date=2015-10-05&rft.eissn=1471-2407&rft.volume=15&rft.spage=652&rft_id=info:doi/10.1186%2Fs12885-015-1663-5&rft_id=info%3Apmid%2F26438237&rft.externalDocID=26438237 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |